TY - JOUR
T1 - Evidence for myosin light chain kinase mediating noradrenaline-evoked cation current in rabbit portal vein myocytes
AU - Aromolaran, A. S.
AU - Albert, A. P.
AU - Large, W. A.
PY - 2000/5/1
Y1 - 2000/5/1
N2 - 1. The role of myosin light chain kinase (MLCK) in the activation of the noradrenaline-evoked non-selective cation current (I(cat)) was examined with the whole-cell recording technique in single rabbit portal vein smooth muscle cells. 2. Intracellular dialysis with 5 μM MLCK((11-19))amide, a substrate-specific peptide inhibitor of MLCK, markedly reduced the amplitude and rate of activation of noradrenaline-evoked I(cat). A similar result was obtained when the cells were dialysed with 10 μM AV25, which also inhibits MLCK by an action at the auto-inhibitory domain of MLCK. 3. Inhibitors of binding of ATP to MLCK, wortmannin and synthetic naphthalenesulphonyl derivatives (ML-7 and ML-9), at micromolar concentrations, also reduced the amplitude of noradrenaline-evoked I(cat). 4. ML-7 and ML-9 (both at 5 μM) reduced the amplitude of I(cat) induced by both guanosine 5'-0-(3-thiotriphosphate) (GTPγS) and 1-oleoyl-2-acetyl-sn-glycerol (OAG). 5. MLCK((11-19))amide, AV25 and ML-9 did not inhibit the noradrenaline-evoked Ca2+-activated potassium current at a holding potential of 0 mV. In addition, MLCK((11-19))amide and AV25 did not reduce the non-selective cation current induced by ATP in rabbit ear artery cells. 6. Intracellular dialysis with 2 μM Ca2+ and 9 μM calmodulin activated I(cat), which developed over a period of about 5 min. 7. Intracellular dialysis with the non-hydrolysable analogue of ATP, 5'-adenylylimidodiphosphate (AMP-PNP), reduced the amplitude and rate of activation of noradrenaline-evoked I(cat). 8. The results indicate that MLCK mediates noradrenaline-activated I(cat) in rabbit portal vein smooth muscle cells.
AB - 1. The role of myosin light chain kinase (MLCK) in the activation of the noradrenaline-evoked non-selective cation current (I(cat)) was examined with the whole-cell recording technique in single rabbit portal vein smooth muscle cells. 2. Intracellular dialysis with 5 μM MLCK((11-19))amide, a substrate-specific peptide inhibitor of MLCK, markedly reduced the amplitude and rate of activation of noradrenaline-evoked I(cat). A similar result was obtained when the cells were dialysed with 10 μM AV25, which also inhibits MLCK by an action at the auto-inhibitory domain of MLCK. 3. Inhibitors of binding of ATP to MLCK, wortmannin and synthetic naphthalenesulphonyl derivatives (ML-7 and ML-9), at micromolar concentrations, also reduced the amplitude of noradrenaline-evoked I(cat). 4. ML-7 and ML-9 (both at 5 μM) reduced the amplitude of I(cat) induced by both guanosine 5'-0-(3-thiotriphosphate) (GTPγS) and 1-oleoyl-2-acetyl-sn-glycerol (OAG). 5. MLCK((11-19))amide, AV25 and ML-9 did not inhibit the noradrenaline-evoked Ca2+-activated potassium current at a holding potential of 0 mV. In addition, MLCK((11-19))amide and AV25 did not reduce the non-selective cation current induced by ATP in rabbit ear artery cells. 6. Intracellular dialysis with 2 μM Ca2+ and 9 μM calmodulin activated I(cat), which developed over a period of about 5 min. 7. Intracellular dialysis with the non-hydrolysable analogue of ATP, 5'-adenylylimidodiphosphate (AMP-PNP), reduced the amplitude and rate of activation of noradrenaline-evoked I(cat). 8. The results indicate that MLCK mediates noradrenaline-activated I(cat) in rabbit portal vein smooth muscle cells.
UR - http://www.scopus.com/inward/record.url?scp=0034192577&partnerID=8YFLogxK
U2 - 10.1111/j.1469-7793.2000.00853.x
DO - 10.1111/j.1469-7793.2000.00853.x
M3 - Article
C2 - 10790163
AN - SCOPUS:0034192577
SN - 0022-3751
VL - 524
SP - 853
EP - 863
JO - Journal of Physiology
JF - Journal of Physiology
IS - 3
ER -